Merus (Netherlands)

Recent papers from Merus (Netherlands)

1. Petosemtamab plus pembrolizumab as first-line (1L) treatment of PD-L1 high metastatic non-small cell lung cancer (NSCLC): Global phase 2 trial.Journal of Clinical Oncology · 2026
2. Abstract 5534: INCA036873, a first-in-class CD70×CD3 T cell-redirecting bispecific antibody, for the treatment of CD70-positive malignanciesCancer Research · 2026
3. Continued zenocutuzumab treatment beyond progression in patients with NRG1+ pancreatic cancer and cholangiocarcinoma: Analysis from the phase 2 eNRGy trial.Journal of Clinical Oncology · 2026
4. LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCCFuture Oncology · 2025
5. Petosemtamab, a Bispecific Antibody Targeting Epidermal Growth Factor Receptor (EGFR) and Leucine-Rich G Repeat-Containing Protein-Coupled Receptor (LGR5) Designed for Broad Clinical ApplicationsCancers · 2025
6. Systemic immunomodulation by irreversible electroporation versus stereotactic ablative body radiotherapy in locally advanced pancreatic cancer: the CROSSFIRE trialJournal for ImmunoTherapy of Cancer · 2025
7. Efficacy of Zenocutuzumab in NRG1 Fusion–Positive CancerNew England Journal of Medicine · 2025
8. Examining Malaysia's Low-Income Housing Environment: A Quantitative Study of the Low-Income Housing Environment's Impact on Residents' Attitudes and Quality of LifePLANNING MALAYSIA · 2025
9. HLA I immunopeptidome of synthetic long peptide pulsed human dendritic cells for therapeutic vaccine designnpj Vaccines · 2025
10. Petosemtamab (MCLA-158) with pembrolizumab as first-line (1L) treatment of recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): Phase 2 study.Journal of Clinical Oncology · 2024
11. Phase I study of MCLA-145, a bispecific antibody targeting CD137 and PD-L1, in solid tumors, as monotherapy or in combination with pembrolizumab.Journal of Clinical Oncology · 2024
12. Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in non-small-cell lung cancer (NSCLC) with c-METexon 14 skipping mutations (METex14).Journal of Clinical Oncology · 2024
13. Transcriptionally Active Human Papillomavirus Infection in a Minority of Esophageal Squamous Cell Carcinomas in North AmericaThe American Journal of Surgical Pathology · 2024
14. Abstract 1903: Zenocutuzumab, a HER2xHER3 bispecific antibody, is effective in cancer models with high NRG1 expressionCancer Research · 2024
15. The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusionsFuture Oncology · 2024
16. Fine-tuning of Fgf8 morphogen gradient by heparan sulfate proteoglycans in the extracellular matrix2023
17. Development of Plasmodium falciparum liver-stages in hepatocytes derived from human fetal liver organoid culturesNature Communications · 2023
18. Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trialSHILAP Revista de lepidopterología · 2023
19. Validation of Adapted Neutralization Assays Developed to Discriminate Anti-Rabies Virus Activity of Two Different Anti-Rabies Virus Monoclonal Antibodies Administered as a CombinationBiologics · 2023
20. Antibodies as drugs—a Keystone Symposia reportAnnals of the New York Academy of Sciences · 2022